Rectal carcinoids are on the rise: early detection by screening endoscopy

 

 Buy Article Permissions and Reprints

Background

Colorectal cancer (colorectal adenocarcinoma) is largely preventable with regular screening and is treatable if detected early. Thanks to screening, the death rate from colorectal cancer is steadily declining in (Western) countries with established screening facilities.

Although adenocarcinoma is the most prevalent colorectal neoplasm, it is not the only one. The age-adjusted incidence of well-differentiated neuroendocrine tumors and cancers of the colorectum (colorectal carcinoids) is about 1 in 100 000 [1]. The Surveillance, Epidemiology, and End Results (SEER) registry database of the National Cancer Institute (which reflects the standard of care for the average US citizen) shows that the age-adjusted incidence of rectal carcinoids has increased about tenfold over the last 35 years [1] [2]. In the United States, 50 % or more of rectal carcinoids are nowadays diagnosed as “incidentally” identified lesions, due to the increased availability and use of screening sigmoidoscopy and/or colonoscopy [2]. The prevalence of rectal carcinoids in adults undergoing screening endoscopy (mean/median age: 48.8 – 54 years) is known to be 0.05 % – 0.07 % [3] [4].

In 2006, 57.1 % of US men and women aged 50 years or older reported they had undergone at least one examination with flexible sigmoidoscopy or colonoscopy [5]. Since about 55 000 000 US citizens have been “scoped,” on the basis of a prevalence rate of 0.05 % – 0.07 % one would expect some 27 500 – 38 500 rectal carcinoids to have been diagnosed “incidentally” by screening endoscopy in the United States. This is the reason why rectal carcinoids have recently attracted our attention.

Due to a lack of controlled prospective studies, the management of rectal carcinoids is a matter of debate. In this report the retrospective data from large national registries and large hospital series are reviewed.

As concerns nomenclature, (well-differentiated) neuroendocrine neoplasms of the rectum that either show angioinvasion or infiltration of the muscularis propria (or beyond) or have metastasized are called neuroendocrine carcinomas. The term “rectal carcinoid” does not distinguish between well-differentiated neuroendocrine carcinoma and well-differentiated neuroendocrine tumor (of the rectum); it comprises both [6].

References

• 1 Modlin I, Oberg K, Chung D. et al . Gastroenteropancreatic neuroendocrine tumours.  Lancet Oncol. 2008;  9 61-72
  CrossrefPubMedGoogle Scholar
• 2 Modlin I, Drozdov I, Gustafsson B. et al .Rectal neuroendocrine tumors – diagnosis and treatment. In: Modlin I, Oberg K (eds). A century of advances in neuroendocrine tumor biology and treatment. Hannover; Felsenstein CCCP 2007: 124-133
  Google Scholar
• 3 Kaminski M, Polkowski M, Regula J. et al . Prevalence and endoscopic features of rectal neuroendocrine tumors (carcinoids) among 50 148 participants of the Polish colorectal-cancer screening programme.  Gut. 2007;  56 (Suppl III) A310
  CrossrefPubMedGoogle Scholar
• 4 Matsui K, Iwase T, Kitagawa M. Small, polypoid-appearing carcinoid tumors of the rectum: clinicopathologic study of 16 cases and effectiveness of endoscopic treatment.  Am J Gastroenterol. 1993;  88 1949-1953
  PubMedGoogle Scholar
• 5 Scherübl H. Options for gastroenteropancreatic neuroendocrine tumours.  Lancet Oncol. 2008;  9 203
  CrossrefPubMedGoogle Scholar
• 6 Soga J. Early-stage carcinoids of the gastrointestinal tract: an analysis of 1914 reported cases.  Cancer. 2005;  103 1587-1595
  CrossrefPubMedGoogle Scholar
• 7 Konishi T, Watanabe T, Kishimoto J. et al . Prognosis and risk factors of metastasis in colorectal carcinoids: results of a nationwide registry over 15 years.  Gut.. 2007;  56 863-868
  CrossrefPubMedGoogle Scholar
• 8 Konishi T, Watanabe T, Muto T. et al . Risk factors for lymph node and distant metastasis in colorectal carcinoids: an analysis of nationwide registry in Japan over 15 years.  J Clin Oncol. 2006;  24 ASCO Abstract 3620
  PubMedGoogle Scholar
• 9 Konishi T, Watanabe T, Kishimoto J. et al . Prognosis and metastatic potential of colorectal carcinoids compared with adenocarcinomas: results of a nationwide registry over 15 years.  J Clin Oncol. 2008;  26 ASCO Abstract 4054
  PubMedGoogle Scholar
• 10 Sauven P, Ridge J, Quan S. et al . Anorectal carcinoid tumors. Is aggressive surgery warranted?.  Ann Surg. 1990;  211 67-71
  PubMedGoogle Scholar
• 11 Tsukamoto S, Fujita S, Yamaguchi T. et al . Clinicopathological characteristics and prognosis of rectal well-differentiated neuroendocrine tumors.  Int J Colorectal Dis. 2008;  23 1109-1113
  CrossrefPubMedGoogle Scholar
• 12 Modlin I, Lye K, Kidd M. A 5-decade analysis of 13 715 carcinoid tumors.  Cancer. 2003;  97 934-959
  CrossrefPubMedGoogle Scholar
• 13 Shim K, Yang S, Myung S. et al . Atypical endoscopic features of rectal carcinoids.  Endoscopy. 2004;  36 313-316
  Article in Thieme ConnectPubMedGoogle Scholar
• 14 Wang A, Ahmad N. Rectal carcinoids.  Curr Opin Gastroenterol. 2006;  22 529-535
  CrossrefPubMedGoogle Scholar
• 15 Kim B N, Sohn D K, Hong C W. et al . Atypical endoscopic features can be associated with metastasis in rectal carcinoid tumors.  Surg Endosc. 2008;  22 1992-1996
  CrossrefPubMedGoogle Scholar
• 16 Kwaan M, Goldberg J, Bleday R. et al . Rectal carcinoid tumors: review of results after endoscopic and surgical therapy.  Arch Surg. 2008;  143 471-475
  CrossrefPubMedGoogle Scholar
• 17 Ramage J, Goretzki P, Manfredi R. et al . Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated colon and rectum tumour/carcinoma.  Neuroendocrinology. 2008;  87 31-39
  CrossrefPubMedGoogle Scholar
• 18 Shinohara T, Hotta T, Oyama T. Rectal carcinoid tumor, 6 mm in diameter, with lymph node metastases.  Endoscopy. 2008;  40 (Suppl 2) E40-E41
  Article in Thieme ConnectPubMedGoogle Scholar
• 19 Scherübl H, Bader M, Fett U. et al . Somatostatin-receptor imaging of neuroendocrine gastroenteropancreatic tumors.  Gastroenterology. 1993;  105 1705-1709
  PubMedGoogle Scholar
• 20 Sakata H, Iwakiri R, Ootani A. et al . A pilot randomised controlled study to evaluate endoscopic resection using a ligation device for rectal carcinoid tumors.  World J Gastroenterol. 2006;  12 4026-4028
  PubMedGoogle Scholar
• 21 Mashimo Y, Matsuda T, Uraoka T. et al . Endoscopic submucosal resection with a ligation device is an effective and safe treatment for carcinoid tumors in the lower rectum.  J Gastroenterol Hepatol. 2008;  23 218-221
  CrossrefPubMedGoogle Scholar
• 22 Onozato Y, Kakizaki S, Ishihara H. et al . Endoscopic submucosal dissection for rectal tumors.  Endoscopy. 2007;  39 423-427
  Article in Thieme ConnectPubMedGoogle Scholar
• 23 Kim Y J, Lee S K, Cheon J H. et al . Efficacy of endoscopic resection for small rectal carcinoid: a retrospective study.  Korean J Gastroenterol. 2008;  51 174-180
  PubMedGoogle Scholar
• 24 Kobayashi K, Katsumata T, Yoshizawa S. et al . Indications of endoscopic polypectomy for rectal carcinoid tumors and clinical usefulness of endoscopic ultrasonography.  Dis Colon Rectum. 2005;  48 285-291
  CrossrefPubMedGoogle Scholar
• 25 Scherübl H. Comment on Ramage et al.: Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated colon and rectum tumour/carcinoma.  Neuroendocrinology. 2008;  88 157-159
  CrossrefPubMedGoogle Scholar
• 26 Höpfner M, Schuppan D, Scherübl H. Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor receptors and their signaling pathways: recent advances and future perspectives.  World J Gastroenterol. 2008;  14 2461-2473
  CrossrefPubMedGoogle Scholar

H. ScherüblMD, PhD 

Klinik für Innere Medizin
Gastroenterologie und Gastrointestinale Onkologie
Vivantes-Klinikum am Urban

Dieffenbachstraße 1
10967 Berlin
Germany

Fax: +49-30-130225205

Email: hans.scheruebl@vivantes.de